Blood clots are masses of blood that change from liquid to gel and can block blood vessels, causing conditions such as deep vein thrombosis and pulmonary embolism.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
The Phase III MAJESTY study met its primary endpoint, showing significantly more people achieved complete remission at two years with Gazyva versus tacrolimus. If approved, Gazyva would be the first therapy specifically indicated for primary membranous nephropathy.
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
International researchers have identified a specific antibody mutation that causes rare but serious blood clots after adenovirus-based COVID-19 vaccines or natural adenovirus infection, providing a roadmap for safer vaccine design.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07378514 |
Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices |
NOT_YET_RECRUITING | |
| NCT06975969 |
Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter |
WITHDRAWN | |
| NCT03805672 |
Below Knee DVT Study |
TERMINATED | PHASE4 |
| NCT02108041 |
Personalized Medicine Decision-Making in a Virtual Clinical Setting |
COMPLETED |
